US11884979B2 - RNA biomarkers for hereditary angioedema - Google Patents

RNA biomarkers for hereditary angioedema Download PDF

Info

Publication number
US11884979B2
US11884979B2 US16/333,177 US201716333177A US11884979B2 US 11884979 B2 US11884979 B2 US 11884979B2 US 201716333177 A US201716333177 A US 201716333177A US 11884979 B2 US11884979 B2 US 11884979B2
Authority
US
United States
Prior art keywords
mir
hsa
subject
level
hae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/333,177
Other languages
English (en)
Other versions
US20190241961A1 (en
Inventor
Daniel J. Sexton
Malini Viswanathan
Ryan Faucette
Tripti Gaur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to US16/333,177 priority Critical patent/US11884979B2/en
Publication of US20190241961A1 publication Critical patent/US20190241961A1/en
Assigned to DYAX CORP. reassignment DYAX CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VISWANATHAN, Malini, FAUCETTE, RYAN, GAUR, Tripti, SEXTON, DANIEL J.
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DYAX CORP.
Application granted granted Critical
Publication of US11884979B2 publication Critical patent/US11884979B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Definitions

  • the plasma contact activation system is a pro-inflammatory and pro-coagulant system involving a group of plasma proteases. It is activated by either factor XIIa upon exposure to foreign or negatively charged surfaces or on endothelial cell surfaces by prolylcarboxypeptidases (Sainz I. M. et al., Thromb. Haemost . (2007) 98, 77-83). Inappropriate or unregulated activation of the contact system has been implicated in various diseases, including hereditary angioedema (HAE).
  • HAE hereditary angioedema
  • HAE ulcerative colitis
  • biomarkers for HAE It is therefore of great interest to identify biomarkers for HAE and develop reliable diagnostic and prognostic methods for identifying subjects having certain types of HAE or being at risk of suffering an acute HAE attack. Such biomarkers would also benefit the studies on disease mechanisms, which could facilitate the development of effective new therapies for the disease.
  • RNA biomarkers that are differentially present in biological samples obtained from subjects having diseases associated with the contact activation system as compared to healthy individuals and/or differentially present in biological samples obtained from subjects in different disease states (e.g., attack versus basal).
  • one aspect of the present disclosure provides methods of analyzing a sample comprising (i) providing a biological sample (e.g., serum sample or a plasma sample) obtained from a subject, such as a human subject, having, suspected of having, or being at risk for a disease associated with the contact activation system; and (ii) measuring the level of a RNA biomarker set, which comprises at least one RNA biomarker selected from Table 1, wherein if the biomarker set consists of one RNA biomarker, said RNA biomarker is not hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-19a-3p, or hsa-miR-20a-5p.
  • the disease associated with the contact activation system is hereditary angioedema (HAE), such as type 1 HAE or type II HAE.
  • HAE hereditary angioedema
  • the biomarker set consists of 2-10 RNA biomarkers selected from Table 1.
  • the RNA biomarker is a messenger RNA encoding a mitochondrial protein, which can be mitochondrially-encoded cytochrome C oxidase III (MT-CO3) or mitochondrially-encoded oxidoreductase core subunit (MT-ND3).
  • the RNA biomarker is a microRNA (e.g., hsa-miR-423-3p, hsa-miR-1307-3p, hsa-miR-355-3p, hsa-miR-485-5p, hsa-miR-16-5p, hsa-miR-19a-3p, hsa-miR-20a-5p, hsa-miR-17-5p, hsa-miR-885-5p, hsa-miR-335-3p, hsa-miR-485-5p).
  • a microRNA e.g., hsa-miR-423-3p, hsa-miR-1307-3p, hsa-miR-355-3p, hsa-miR-485-5p, hsa-miR-16-5p, hsa-miR-19a-3p, hsa-mi
  • the level of a RNA biomarker set can be measured by a process involving polymerase chain reaction and/or nucleic acid hybridization.
  • the method further comprises identifying the subject as having a disease associated with the contact system, if the level of the RNA biomarker set of the subject deviates from the level of the same RNA biomarker set of a control subject.
  • the method further comprises administering to the subject an effective amount of a therapeutic agent for treating the disease, such as a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor inhibitor, and/or a C1 esterase inhibitor, if the subject is identified as having the disease.
  • a therapeutic agent for treating the disease such as a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor inhibitor, and/or a C1 esterase inhibitor, if the subject is identified as having the disease.
  • the pKal inhibitor is an anti-pKal antibody (e.g., lanadelumab) or an inhibitory peptide (e.g., ecallantide).
  • the bradykinin 2 receptor inhibitor is an inhibitory peptid
  • the subject is a human patient who is on a treatment for the disease
  • the method further comprises assessing the efficacy of the treatment based on the level of the RNA biomarker set, a deviation of the level of the RNA biomarker set of the subject from that of a control subject being indicative of the treatment efficacy.
  • the method further comprises identifying a suitable treatment for the subject based on the level of the RNA biomarker set.
  • the method further comprises identifying the subject as a candidate for a treatment of the disease based on the level of the RNA biomarker set.
  • the RNA biomarker set comprises on or more RNA biomarkers selected from the group consisting of hsa-miR-1307-3p, hsa-miR-335-3p, and hsa-miR-485-5p.
  • the method further comprises assessing the risk of disease attack in the subject based on the level of the RNA biomarker set, a deviation of the RNA biomarker set level of the subject from that of a control subject being indicative of the risk of a disease attack.
  • RNA biomarkers capable of identifying patients with diseases associated with the contact activation system (e.g., HAE). Measuring the levels of the biomarker sets may also be useful in the evaluation and treatment of such diseases.
  • HAE contact activation system
  • a kit for analyzing a sample of a subject having, suspected of having, or at risk for a disease associated with the contact system, the kit comprising a first binding agent specific to a first RNA biomarker selected from Table 1; and a second binding agent specific to a second RNA biomarker selected from Table 1; wherein the first RNA biomarker and the second RNA biomarker are different.
  • the first binding agent is an oligonucleotide complementary (completely or partially) to the first RNA biomarker and/or the second binding agent is an oligonucleotide complementary (completely or partially) specific to the second RNA biomarker.
  • the first binding agent and the second binding agent may be immobilized on a support member.
  • the first binding agent and/or the second binding agent is conjugated to a label (e.g., fluorescent label).
  • FIG. 1 is a graph showing increased transcript levels for mitochondrial cytochrome oxidase (MT-CO3) and mitochondrial NADH dehydrogenase (MT-ND3) during both HAE in quiescence (HAE during basal state) and HAE during attack.
  • the fold change of each transcript is shown as measured by sequencing and by RT-qPCR.
  • FIG. 2 presents graphs showing levels of selected microRNA levels in plasma samples obtained from healthy individuals and HAE patients.
  • A fold change of RNA transcript in quiescence (HAE in basal state) compared to healthy individual (“HV”).
  • B fold change of RNA transcript in HAE during attack compared to healthy individual (“HV”).
  • C fold change of RNA transcript in HAE during attack compared to quiescence (HAE in basal state).
  • FXII Factor XII
  • Hageman Factor is a serine protease that plays a role in activation of the intrinsic pathways of coagulation as well as the kallikrein-kinin system.
  • FXII is activated by negatively charged surfaces (e.g., polyanionic surfaces, glass, polyphosphate, ellagic acid) to produce the active form FXIIa.
  • Activated FXIIa has the ability to cleave pre-kallikrein, generating active pKal.
  • activated pKal is able to cleave FXII into FXIIa, resulting in a positive feedback loop in which FXIIa generates even more pKal, which further activates additional FXII into FXIIa.
  • Activated pKal is also able to cleave high molecular weight kininogen (HMWK) to release bradykinin.
  • HMWK high molecular weight kininogen
  • RNAs nucleic acids
  • RNAs e.g., microRNAs and RNA transcripts encoding proteins
  • RNAs e.g., microRNAs and RNA transcripts encoding proteins
  • RNAs e.g., microRNAs and RNA transcripts encoding proteins
  • RNAs were identified as differentially present in biological samples obtained from subjects during an attack of a disease of the contact activation system as compared to subjects having the disease at quiescent (basal) state.
  • RNA biomarker set e.g., HAE
  • Such methods may be useful, e.g., for identifying patients who are at risk of a disease associated with the contact activation system (e.g., HAE), selecting a candidate for treatment, monitoring disease progression or disease state, assessing the efficacy of a treatment against a disease, determining a course of treatment, assessing whether a subject is at risk for an attack of the disease, identifying whether a disease or disorder is associated with the contact activation system, and/or for research purposes, including, e.g., studying the mechanism of a disease and/or biological pathways/processes involved in the disease, which may be relied upon for the development of new therapies.
  • a disease associated with the contact activation system e.g., HAE
  • studying the mechanism of a disease and/or biological pathways/processes involved in the disease which may be relied upon for the development of new therapies.
  • RNA biomarker or “RNA biomarker set” refers to a RNA or set of RNAs that are present at different levels in samples from different groups of subjects, for example, subjects having a disease associated with the contact system versus healthy subjects (e.g., subjects who are free of the disease), or subjects having the disease and being at the quiescence stage versus subjects under the attack of the disease.
  • Such biomarker/biomarker sets may be used in both diagnostic/prognostic applications and non-clinical applications, for example, for research purposes.
  • a RNA biomarker may be present at an elevated level in samples from subjects having a disease associated with the contact activation system (e.g., HAE) as compared to the level of the same RNA biomarker in samples from healthy subjects.
  • a RNA biomarker may be present at a reduced level in samples from subjects having a disease associated with the contact activation system (e.g., HAE) as compared to the level of the biomarker in samples from healthy subjects.
  • a RNA biomarker may be present at an elevated level in samples obtained from subjects under attack of a disease as described herein as compared with subjects during disease quiescence.
  • a RNA biomarker may be present at a reduced level in samples obtained from subjects under attack of a disease as described herein as compared with subjects during disease quiescence.
  • a RNA biomarker set containing one or more biomarkers can be analyzed in the methods described herein.
  • the RNA biomarker set contains more than one biomarker, all of the biomarkers may present at elevated levels or reduced levels in subjects having a disease as compared with health subjects.
  • a RNA biomarker set may contain at least one biomarker that is elevated in subjects having the disease as compared with healthy subjects and at least one biomarker that is reduced in subjects having the disease as compared with healthy subjects.
  • RNA biomarker set for differentiating subjects under attack of a disease from subjects in disease quiescence
  • the biomarker set may contain multiple biomarkers that are all elevated or reduced in a first disease stage (e.g., attack) as compared with a second disease stage (e.g., quiescence).
  • the biomarker set may contain at least one biomarker that is elevated in the first disease stage as compared with the second disease stage and at least one biomarker that is reduced in the first disease stage as compared with the second disease stage.
  • Table 1 below provides RNA biomarkers that can be evaluated by the methods described herein evaluate subjects or biological samples from subjects for diseases associated with the contact activation system.
  • RNA Grouping RNA Biomarker Mitochondrial Function Mitochondrially-Encoded Cytochrome C Oxidase III (MT-CO3) Mitochondrially-Encoded NADH-Ubiquinone Oxidoreductase Core Subunit 3 (MT-ND3) MicroRNA Hsa-miR-423-3p Hsa-miR-1307-3p* Hsa-miR-485-5p Hsa-miR-16-5p Hsa-miR-19a-3p Hsa-miR-20a-5p Hsa-miR-17-5p Hsa-miR-885-5p Hsa-miR-335-3p* Hsa-miR-485-5p* *Indicates RNAs that were identified as being differentially present in samples from HAE patients during an attack as compared to HAE patients during quiescence.
  • the biomarker set to be measured and analyzed in any of the methods described herein includes at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) RNAs selected from Table 1.
  • RNA biomarker may not be hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-19a-3p, or hsa-miR-20a-5p.
  • the RNA biomarker set to be measured and analyzed in a method described herein does not include a combination of any one of hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-19a-3p, and hsa-miR-20a-5p.
  • RNAs encoding proteins involved in similar cellular processes and pathways were differentially present in samples from subjects having HAE as compared to healthy subjects. This data indicates that the RNAs shown in Table 1 may play a role in or be affected by diseases associated with the contact system.
  • RNA biomarkers described herein may be characterized as “involved in” or “associated with” a particular pathway or activity.
  • the terms “involved in” or “associated with” refer to a RNA that contributes to pathway.
  • a RNA such as an RNA that encodes a protein or a microRNA, that is involved in or associated with a pathway may perform a function within the pathway (e.g., regulate expression of another nucleic acid or activity of a protein) or encode a molecule (e.g., a protein) that performs a function within the pathway or cellular process.
  • the RNA biomarker set includes one or more RNAs that encode mitochondrial proteins as listed in Table 1.
  • the RNA biomarker set includes one or more microRNA, e.g., one or more microRNAs selected from Table 1.
  • the biomarker set includes one or more microRNA, e.g., one or more microRNA selected from Table 1.
  • One aspect of the present disclosure relates to methods for analyzing samples obtained from subjects (e.g., human patients) having, suspected of having, or being at risk for a disease associated with the contact activation system by measuring the level of a biomarker set as described herein in the sample. Results obtained from such assay methods would be useful for diagnostic and/or prognostic purposes, as well as for other non-clinical purposes, such as research purposes.
  • a biological sample refers to a composition that comprises tissue, e.g., blood, plasma or protein, from a subject.
  • a sample includes both an initial unprocessed sample taken from a subject as well as subsequently processed, e.g., partially purified or preserved forms. Exemplary samples include blood, plasma, tears, or mucus.
  • the sample is a body fluid sample such as a serum or plasma sample.
  • multiple biological samples may be collected from subject, over time or at particular time intervals, for example to assess the disease progression or evaluate the efficacy of a treatment.
  • a biological sample can be obtained from a subject using any means known in the art.
  • the sample is obtained from the subject by collecting the sample (e.g., a blood sample) into an evacuated collection tube (e.g., an evacuated blood collection tube).
  • the evacuated collection tube contains one or more protease inhibitors, for example, to reduce or prevent ex vivo activation of the contact system during sample collection.
  • protease inhibitors may be contained in a liquid formulation.
  • the protease inhibitors comprise at least one serine protease inhibitor and at least one cysteine protease inhibitor.
  • Such evacuated collection tubes are known in the art. See, for example, PCT Application No. US2016/046681.
  • an evacuated blood collection tube may further comprise one or more anti-coagulants.
  • a subject who needs the analysis as described herein.
  • the subject is a human or a non-human mammal.
  • a subject is suspected of or is at risk for a disease or disorder associated with the contact activation system (e.g., HAE).
  • HAE contact activation system
  • Such a subject may exhibit one or more symptoms associated with the disease.
  • a subject may carry one or more risk factors for the disease, for example, a genetic factor associated with the disease (e.g., a genetic defect in CI-INH).
  • the subject who needs the analysis described herein may be a patient of the disease.
  • a subject may be under the attack of the disease currently, or may suffer from the disease in the past (e.g., during disease quiescence currently).
  • the subject is a human patient who may be on a treatment of the disease, for example, a treatment involving a C1 esterase inhibitor (C1-INH), a plasma kallikrein inhibitor, or a bradykinin inhibitor.
  • C1-INH C1 esterase inhibitor
  • plasma kallikrein inhibitor e.g., a plasma kallikrein inhibitor
  • a bradykinin inhibitor e.g., bradykinin inhibitor
  • diseases associated with the contact activation system include, without limitation, kallikrein-mediated disorders, e.g., a bradykinin-mediated disorder, such as hereditary angioedema (HAE), non-histamine-dependent idiopathic angioedema, rheumatoid arthritis, Crohn's disease, lupus, Alzheimer's disease, septic shock, burn injury, brain ischemia/reperfusion injury, cerebral edema, diabetic retinopathy, diabetic nephropathy, macular edema, vasculitis, arterial or venous thrombosis, thrombosis associated with ventricular assist devices or stents, heparin-induced thrombocytopenia with thrombosis, thromboembolic disease, and coronary heart disease with unstable angina pectoris, edema, eye disease, gout, intestinal bowel disease, oral mucositis, neuropathic pain, inflammatory pain, spinal sten,
  • the disease or condition that is associated with the contact activation system is hereditary angioedema (HAE).
  • Hereditary angioedema HAE is also known as “Quincke edema,” C1 esterase inhibitor deficiency, C1 inhibitor deficiency, and hereditary angioneurotic edema (HANE).
  • HAE is characterized by recurrent episodes of severe swelling (angioedema), which can affect, e.g., the limbs, face, genitals, gastrointestinal tract, and airway.
  • Symptoms of HAE include, e.g., swelling in the arms, legs, lips, eyes, tongue, and/or throat; airway blockage that can involve throat swelling and sudden hoarseness; repeat episodes of abdominal cramping without obvious cause; and/or swelling of the intestines, which can be severe and can lead to abdominal cramping, vomiting, dehydration, diarrhea, pain, and/or shock.
  • About one-third of individuals with HAE develop a non-itchy rash called erythema marginatum during an attack.
  • HAE head-to-edema
  • Trauma or stress e.g., dental procedures, sickness (e.g., viral illnesses such as colds and the flu), menstruation, and surgery can trigger an attack of angioedema.
  • sickness e.g., viral illnesses such as colds and the flu
  • menstruation e.g., menstruation
  • surgery can trigger an attack of angioedema.
  • HAE HAE affects 1 in 50,000 people
  • type I accounts for about 85 percent of cases
  • type II accounts for about 15 percent of cases
  • type III is very rare.
  • Type III is the most newly described form and was originally thought to occur only in women, but families with affected males have been identified.
  • HAE is inherited in an autosomal dominant pattern, such that an affected person can inherit the mutation from one affected parent. New mutations in the gene can also occur, and thus HAE can also occur in people with no history of the disorder in their family. It is estimated that 20-25% of cases result from a new spontaneous mutation.
  • the SERPING1 gene provides instructions for making the C1 inhibitor protein, which is important for controlling inflammation.
  • C1 inhibitor blocks the activity of certain proteins that promote inflammation. Mutations that cause hereditary angioedema type I lead to reduced levels of C1 inhibitor in the blood. In contrast, mutations that cause type II result in the production of a C1 inhibitor that functions abnormally. Without the proper levels of functional C1 inhibitor, excessive amounts of bradykinin are generated. Bradykinin promotes inflammation by increasing the leakage of fluid through the walls of blood vessels into body tissues. Excessive accumulation of fluids in body tissues causes the episodes of swelling seen in individuals with hereditary angioedema type I and type II.
  • Mutations in the F12 gene are associated with some cases of hereditary angioedema type III.
  • the F12 gene provides instructions for making coagulation factor XII.
  • factor XII is also an important stimulator of inflammation and is involved in the production of bradykinin.
  • Certain mutations in the F12 gene result in the production of factor XII with increased activity. As a result, more bradykinin is generated and blood vessel walls become more leaky, which leads to episodes of swelling.
  • the cause of other cases of hereditary angioedema type III remains unknown. Mutations in one or more as-yet unidentified genes may be responsible for the disorder in these cases.
  • HAE can present similarly to other forms of angioedema resulting from allergies or other medical conditions, but it differs significantly in cause and treatment.
  • HAE is misdiagnosed as an allergy, it is most commonly treated with antihistamines, steroids, and/or epinephrine, which are typically ineffective in HAE, although epinephrine can be used for life-threatening reactions.
  • Misdiagnoses have also resulted in unnecessary exploratory surgery for patients with abdominal swelling, and in some HAE patients abdominal pain has been incorrectly diagnosed as psychosomatic.
  • C1 inhibitor concentrate from donor blood which is administered intravenously, is one acute treatment; however, this treatment is not available in many countries.
  • fresh frozen plasma FFP
  • C1 inhibitor concentrate can be used as an alternative, as it also contains C1 inhibitor.
  • C1 inhibitor derived from human blood
  • Berinert which is pasteurized, was approved by the F.D.A. in 2009 for acute attacks.
  • CINRYZE® which is nanofiltered, was approved by the F.D.A. in 2008 for prophylaxis.
  • Rhucin/Ruconest is a recombinant C1 inhibitor under development that does not carry the risk of infectious disease transmission due to human blood-borne pathogens.
  • Treatment of an acute HAE attack also can include medications for pain relief and/or IV fluids.
  • Treatment modalities can stimulate the synthesis of C1 inhibitor, or reduce C1 inhibitor consumption.
  • Androgen medications such as danazol, can reduce the frequency and severity of attacks by stimulating production of C1 inhibitor.
  • H. pylori can trigger abdominal attacks. Antibiotics to treat H. pylori will decrease abdominal attacks.
  • Ecallantide inhibits plasma kallikrein and has been approved in the U.S.
  • Icatibant inhibits the bradykinin B2 receptor, and has been approved in Europe and the U.S.
  • HAE Diagnosis of HAE can rely on, e.g., family history and/or blood tests. Laboratory findings associated with HAE types I, II, and III are described, e.g., in Kaplan, A. P., J Allergy Clin Immunol, 2010, 126(5):918-925.
  • type I HAE the level of C1 inhibitor is decreased, as is the level of C4, whereas C1q level is normal.
  • type II HAE the level of C1 inhibitor is normal or increased; however, C1 inhibitor function is abnormal. C4 level is decreased and C1q level is normal.
  • type III the levels of C1 inhibitor, C4, and C1q can all be normal.
  • RNAs that have differential levels in samples from HAE patients as compared to healthy individuals (Table 1). Measuring the levels of biomarker sets of these RNAs can be used to identify whether a subject has a disease, such as HAE. In some embodiments, the methods may be used to determine whether a patient has had or is having an HAE attack.
  • Symptoms of HAE can be assessed, for example, using questionnaires, e.g., questionnaires that are completed by patients, clinicians, or family members. Such questionnaires are known in the art and include, for example, visual analog scales. See, e.g., McMillan, C. V. et al. Patient. 2012;5(2):113-26.
  • the biological sample described herein can be subject to analysis by measuring the level of a RNA biomarker set as described herein in the biological sample.
  • Levels e.g., the amount
  • a biomarker disclosed herein or changes in levels the biomarker, can be assessed using assays described herein and/or assays known in the art.
  • One or more of the biomarkers described herein may be analyzed using convention methods, for example, PCR, nucleic acid hybridization, or microarray.
  • the level of a biomarker is assessed or measured by directly detecting the RNA biomarker in a biological sample.
  • the RNA biomarker may be amplified by, e.g., PCR, before detection.
  • detection assay used for the detection and/or quantification of a contact activation system biomarker such as those provided herein will depend on the particular situation in which the assay is to be used (e.g., clinical or research applications), and on the kind and number of biomarkers to be detected, and on the kind and number of patient samples to be run in parallel, to name a few parameters.
  • the biomarker is directly measured in the biological sample, for example by contacting the sample with a binding agent that selectively binds to one or more of the RNA biomarkers (e.g., any one of the biomarkers provided in Table 1).
  • the biomarker (the RNA or cDNA corresponding to the RNA biomarker) is detected using a hybridization method, such as contacting the sample with a nucleic acid probe that specification binds to the biomarker, Southern blotting, or Northern blotting methods.
  • the binding agent is an oligonucleotide that is complementary to a RNA biomarker.
  • the oligonucleotides for use in the methods described herein are oligonucleotides (single-strand DNA or RNA molecules) that are complementary (partially or completely) to a region of the RNA biomarker (or a cDNA corresponding to the RNA biomarker).
  • “Complementary,” as used herein, refers to the nucleobase complementarity commonly known in the art. For example, adenine is complementary to thymine (in DNA) or uracil in RNA; and guanine is complementary to cytosine.
  • “Sequence complementarity”, or “nucleic acid sequences being complementary to one another”, as used herein, means when the two nucleic acid molecules are aligned antiparallel to each other, the nucleotide bases at each position, or at most positions in the sequences are complementary, and that the two nucleic acid molecules can hybridize and form a duplex under suitable conditions, e.g., hybridization temperature.
  • sequence complementarity needs not be 100% for the two nucleic acid molecules to hybridize and form a duplex.
  • the sequence complementarity between the oligonucleotide and the RNA biomarker (or a cDNA corresponding to the RNA biomarker) may be at least 80% complementary to the corresponding region in the RNA biomarker.
  • the oligonucleotide contains a fragment that is at least 80% (e.g., 85%, 90%, 95%, 98%, or 100%) complementary to a portion of the RNA biomarker (or cDNA corresponding to the RNA biomarker).
  • the oligonucleotide contains a fragment that is completely complementary (100% complementary) to a portion of the RNA biomarker (or cDNA corresponding to the RNA biomarker).
  • Such an oligonucleotide may be used in differentiating the RNA biomarker from substantially similar nucleic acids, for example, nucleic acids having 1, 2, or 3 base differences relative to the target nucleic acid.
  • the oligonucleotide may contain up to 100 nucleotides (e.g., up to 80 nt, 60 nt, 50 nt, or 30 nt). In some embodiments, the oligonucleotide may be 8-50 nucleotides in length, e.g., 8-40, 8-30, 10-30, 15-30, or 15-20 nucleotides in length. In some examples, the oligonucleotide may be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In some examples, the whole molecule of the oligonucleotide is complementary to a portion of a RNA biomarker.
  • a fragment of oligonucleotide is complementary to a portion of a RNA biomarker.
  • an oligonucleotide may contain a linker (e.g., a poly A or poly T linker) for attaching to a support member.
  • a detecting probe may contain such a linker for conjugating to a label.
  • the fragment of an oligonucleotide that is complementary to a portion of a RNA biomarker may be located at the 5′ end of the oligonucleotide, the 3′ end of the oligonucleotide, or in the middle of the oligonucleotide.
  • the fragment of the oligonucleotide that is complementary to the RNA biomarker may be at least 10-nucleotide long (e.g., at least 12, 15, 18, 20, or 25-nucleotide long).
  • the oligonucleotide comprises one or more modified nucleotides, for example, containing nucleotides modified by a 2′-O-methoxyl group, a 2′-O-methoxyethyl group, and/or a phosphorothioate group.
  • the oligonucleotide comprises one or more locked nucleic acids (LNAs).
  • LNA locked nucleic acids
  • An LNA often referred to as inaccessible RNA, is a modified RNA nucleotide, in which the ribose moiety is modified with an extra bridge connecting the 2′ oxygen and 4′ carbon.
  • LNA nucleotides can be used in both DNA and RNA probes. In some examples, up to 50% (e.g., 40%, 30%, 20%, or 10%) of the nucleotides in the probe are LNAs. In some examples, an oligonucleotide may comprise 10, 8, 6, 5, 4, 3, 2, or 1 LNA.
  • the oligonucleotide can be designed based on the sequence of the RNA biomarker for which detection is desired and be prepared via conventional methods, for example, chemical synthesis or in vitro transcription.
  • the oligonucleotide as described herein can be immobilized on a support member via a conventional method.
  • immobilized means attached, bound, or affixed, covalently or non-covalently, so as to prevent dissociation or loss of the oligonucleotide, but does not require absolute immobility with respect to either the oligonucleotide or the support member.
  • a support member can be a solid or semi-solid member with a surface that can be used to specifically attach, bind or otherwise capture a nucleotide probe (e.g., the oligonucleotide of the present disclosure), such that the nucleotide probe becomes immobilized with respect to the support member.
  • the support member of the present disclosure may be fabricated from one or more suitable materials, for example, plastics or synthetic polymers (e.g., polyethylene, polypropylene, polystyrene, polyamide, polyurethane, phenolic polymers, or nitrocellulose), naturally derived polymers (e.g., latex rubber, polysaccharides, polypeptides), composite materials, ceramics, silica or silica-based materials, carbon, metals or metal compounds (e.g., comprising gold, silver, steel, aluminum, or copper), inorganic glasses, silica, and a variety of other suitable materials.
  • suitable configurations include beads (e.g., magnetic beads), tubes (e.g., nanotubes), plates, disks, dipsticks, chips, microchips, coverslips, or the like.
  • the surface of the support member of the present disclosure may comprise any molecule, other chemical/biological entity, or solid support modification disposed upon the solid support that can be used to specifically attach, bind or otherwise capture a nucleic acid molecule (e.g., an oligonucleotide complementary to an RNA biomarker).
  • a nucleic acid molecule e.g., an oligonucleotide complementary to an RNA biomarker.
  • Surface compositions that may be used to immobilize a nucleic acid molecule can be readily found in the art.
  • the surface may comprise a complementary nucleic acid or a nucleic acid binding protein, which can be attached to the surface via convention methods.
  • the linkage between the nucleic acid to be immobilized (e.g., the oligonucleotide of the present disclosure) and the surface may comprise one or more chemical or physical (e.g., non-specific attachment via van der Waals forces, hydrogen bonding, electrostatic interactions, hydrophobic/hydrophilic interactions; etc.) bonds and/or chemical linkers providing such bond(s).
  • the surface of the support member may comprise reactive functional groups that are capable of forming covalent bonds with the nucleic acid molecules to immobilized.
  • the functional groups are chemical functionalities.
  • the binding surface may be derivatized such that a chemical functionality is presented at the binding surface, which can react with a chemical functionality on the nucleic acid to be captured, resulting in attachment.
  • functional groups for attachment include, but are not limited to, amino groups, carboxyl groups, epoxide groups, maleimide groups, oxo groups, and thiol groups.
  • Crosslinkers for attaching nucleic acid molecules to a support member are known in the art; for example, homo-or hetero-bifunctional crosslinkers as are well known (e.g., see 1994 Pierce Chemical Company catalog, technical section on crosslinkers, pages 155-200, or “Bioconjugate Techniques” by Greg T. Hermanson, Academic Press, 1996).
  • Non-limiting example of crosslinkers include alkyl groups (including substituted alkyl groups and alkyl groups containing heteroatom moieties), esters, amide, amine, epoxy groups and ethylene glycol and derivatives.
  • a linker may also be a sulfone group, forming a sulfonamide.
  • the functional group is a light-activated functional group. That is, the functional group can be activated by light to attach the capture component to the capture object surface.
  • One example is PhotoLinkTM technology available from SurModics, Inc. in Eden Prairie, MN.
  • support member and the surface composition are not meant to be limiting. Any support members that are known in the art to be suitable for immobilization of nucleic acid molecules may be used in accordance with the methods and kits described herein.
  • the binding agent e.g., oligonucleotide complementary to a RNA biomarker
  • conjugated means the label is attached to the binding agent, covalently or non-covalently.
  • the label agent can be any molecule, particle, or the like, that facilitates detection, directly or indirectly, using a suitable detection technique.
  • the labeling agent may be a molecule or moiety capable of releasing a signal that can be directly interrogated and/or detected (e.g., a fluorescent label or a dye).
  • the label may be a molecule or moiety capable of converting a substrate (e.g., an enzyme) to a product that is capable of releasing a detectable signal.
  • the label may be a luciferase, which converts luciferin to oxyluciferin to emit detectable lights.
  • the label is a binding ligand to a molecule or moiety capable of converting a substrate (e.g., an enzyme), wherein the converted substrate releases detectable signals.
  • the label is a fluorescent label.
  • fluorescent label examples include, but are not limited to, fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine and fluorescent metals such as 152 Eu or other metals from the lanthanide series, CYE dyes, and fluorescent proteins such as eGFP, eYFP, eCFP, mKate2, mCherry, mPlum, mGrape2, mRaspberry, mGrape1, mStrawberry, mTangerine, mBanana, and mHoneydrew.
  • exemplary labels include, but are not limited to, biotin, phosphorescent labels, chemiluminescent labels or bioluminescent labels (such as luminal, isoluminol, theromatic acridinium ester, imidazole, acridinium salts, oxalate ester, and dioxetane), radio-isotopes (such as 3 H, 125 I, 32 P, 35 S, 14 C, 51 Cr, 36 Cl, 57 Co, 58 Co, 59 Fe, and 75 Se), metals, metal chelates or metallic cations (for example metallic cations such as 99 Tc, 123 I, 111 In, 131 I, 97 Ru, 67 Ga, and 68 Ga.
  • biotin such as luminal, isoluminol, theromatic acridinium ester, imidazole, acridinium salts, oxalate ester, and dioxetane
  • radio-isotopes such as
  • chromophores and enzymes e.g., malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, peroxidase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase).
  • malate dehydrogenase staphylococcal nuclease
  • delta-V-steroid isomerase yeast alcohol dehydrogenase
  • alpha-glycerophosphate dehydrogenase e.g., alpha-glycerophosphate dehydrogenase
  • the biomarker is measured using polymerase chain reaction.
  • RNA extracted from the biological sample is subjected to polymerase chain reaction.
  • cDNA corresponding to the RNA of the biological sample is used in the polymerase chain reaction.
  • the nucleic acid may be double stranded or single stranded.
  • Various methods using polymerase chain reaction are known in the art, including reverse transcription RNA, quantitative PCR, and multiplex PCR.
  • polymerase chain reactions rely on cycling through a series of steps including annealing and extension/elongation.
  • a pair of oligonucleotides e.g., primers
  • a desired nucleic acid e.g. a biomarker
  • the reaction proceeds to an extension/elongation step in which a polymerase synthesizes a complementary nucleic acid strand.
  • the double stranded nucleic acid product is denatured and another cycle of the reaction is initiated.
  • the polymerase chain reaction involves different temperature settings for each of the steps of the cycle. In some embodiments, the polymerase chain reaction is performed at a single temperature (e.g., isothermal reaction).
  • nucleic acids corresponding to the RNA biomarker set are selectively amplified and subsequently detected using any method known in the art.
  • the amplified product may be detected using hybridization methods.
  • the amplified product may be detected by one or more modifications introduced during the polymerase chain reaction.
  • a dye, fluorophore or other indicator agent is intercalated into the nucleic acid during the polymerase chain reaction.
  • one or more of the nucleic acid primers may comprise a tag (e.g., a nucleic acid tag) that may be detected.
  • a RNA biomarker is measured using methods involving hybridization, for example with an oligonucleotide that is complementary (partially or completely) to the RNA biomarker.
  • the hybridization method is performed on the biological sample to detect the RNA biomarker or on a composition (e.g., PCR reaction) comprising an amplified product (e.g., amplified RNA biomarker or cDNA corresponding to the RNA biomarker).
  • the hybridization involves contacting the sample with an oligonucleotide (e.g., a probe) that specifically binds to the biomarker.
  • hybridization methods include, without limitation, Southern blotting, Northern blotting, and microarray methods.
  • the oligonucleotide may be conjugated to a label for detection and/or immobilized on a support member.
  • the biomarker is measured using nucleic acid sequencing.
  • the abundance of a particular nucleic acid sequence e.g. of a biomarker
  • the abundance of the same nucleic acid sequence in another sequence e.g., whole transcriptome sequencing, RNASeq.
  • Such comparison can be performed, for example, by comparing the number of reads of a particular sequence between samples.
  • nucleic acid sequencing may be performed using any method known in the art and selection of an appropriate method will be evident to one of ordinary skill in the art.
  • nucleic acid may be sequenced using Sanger sequencing or high-throughput sequencing methods.
  • the biological sample is subjected to a RNA extraction process to isolate the RNA present in the sample (e.g., prior to measuring the biomarker).
  • RNA extraction processes are well known in the art. Examples of RNA extraction processes include commercially available kits and phenol-chloroform extraction.
  • the RNA extracted from the biological sample is subjected to in vitro translation, thereby producing proteins encoded by the RNA, including proteins encoded by a RNA biomarker, if present.
  • the biological sample or the RNA extracted from the biological sample is subjected to reverse transcription, thereby producing cDNA corresponding to the RNA, including the RNA biomarkers, if present.
  • the biomarker is measured using an immunoassay.
  • a biological sample is contacted with a binding agent, such as nucleic acid-binding protein, that binds to a RNA biomarker.
  • An immunoassay may then be performed to detect the binding agent, as an indirect measure of the amount of the biomarker in the sample.
  • immunoassays include, without limitation immunoblotting assays (Western blots), enzyme linked immunosorbent assays (ELISAs) (e.g., sandwich ELISAs), radioimmunoassays, electrochemiluminescence-based detection assays, magnetic immunoassays, lateral flow assays, and related techniques.
  • ELISAs are known in the art (see, e.g., Crowther, John R (2009). “The ELISA Guidebook.” 2nd ed. Humana Press and Lequin R (2005). “Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA)”. Clin. Chem. 51 (12): 2415-8) and exemplary ELISAs are described herein. Kits for performing ELISAs are also known in the art and commercially available (see, e.g., ELISA kits from Life Technologies and BD Biosciences).
  • the immunoassays described herein may be in the format of a sandwich ELISA, in which a first binding agent that specifically binds a binding agent (e.g., a nucleic acid-binding protein that binds to the RNA biomarker) is immobilized on a support member.
  • a binding agent e.g., a nucleic acid-binding protein that binds to the RNA biomarker
  • the support member can then be incubated with a biological sample as described herein for a suitable period of time under conditions that allow for the formation of complex between the binding agent and the biomarker in the sample.
  • Such a complex can then be detected using a detection agent that binds the biomarker, the binding agent-biomarker complex, or the binding agent.
  • the detection agent can be conjugated to a label, as described herein, which can release a signal directly or indirectly.
  • the intensity of the signal represents the level of the RNA biomarker in the sample.
  • the detection agent is detected and
  • any binding agent that specifically binds to a desired nucleic acid may be used in the methods and kits described herein to measure the level of a RNA biomarker in a biological sample.
  • the binding agent is an antibody that specifically binds to a desired nucleic acid.
  • a sample may be contacted, simultaneously or sequentially, with more than one binding agent that bind different RNAs (e.g., multiplexed analysis, for example the SOMAScanTM assay (SOMALogic)).
  • SOMAScanTM assay SOMALogic
  • the term “contact” refers to an exposure of the binding agent with the biological sample or agent for a suitable period sufficient for the formation of complexes between the agent and the RNA in the sample, if any.
  • the contacting is performed by capillary action in which a biological sample or agent is moved across a surface of the support membrane.
  • the immunoassays may be performed on low-throughput platforms, including in single immunoassay format.
  • a low throughput platform may be used to measure the presence and amount of a nucleic acid in biological samples (e.g., biological tissues, tissue extracts) for diagnostic methods, monitoring of disease and/or treatment progression, and/or predicting whether a disease or disorder may benefit from a particular treatment.
  • the support member it may be necessary to immobilize a binding agent to the support member.
  • Methods for immobilizing a binding agent will depend on factors such as the nature of the binding agent and the material of the support member and may require particular buffers. Such methods will be evident to one of ordinary skill in the art.
  • the biomarker set in a biological sample as described herein may be measured using any of the kits and/or detecting devices which are also described herein.
  • the terms “measuring” or “measurement,” or alternatively “detecting” or “detection,” mean assessing the presence, absence, quantity or amount (which can be an effective amount) of a substance within a sample, including the derivation of qualitative or quantitative concentration levels of such substances, or otherwise evaluating the values or categorization of a subject.
  • Assays may further involve use of a quantitative imaging system, e.g., LICOR imaging technology, which is commercially available (see, e.g., the Odyssey® CLx infrared imaging system from LI-COR Biosciences).
  • LICOR imaging technology which is commercially available (see, e.g., the Odyssey® CLx infrared imaging system from LI-COR Biosciences).
  • an electrochemiluminescence detection assay or an assay relying on a combination of electrochemiluminescence and patterned array technology is used (e.g., an ECL or MULTI-ARRAY technology assay from Meso Scale Discovery (MSD)).
  • the level of a RNA of a biomarker set can be compared to the level of the RNA in a control sample or a reference sample.
  • RNA biomarker set can be applied for the evaluation of a disease associated with the contact activation system, such as those described herein.
  • RNAs presented in Table 1 detected in samples from subjects can be used as reliable biomarkers for diagnosing diseases associated with the contact activation system (e.g., HAE), monitoring the progress of such a disease, assessing the efficacy of a treatment for the disease, identifying patients suitable for a particular treatment, and/or predicting disease attack in a subject.
  • diseases associated with the contact activation system e.g., HAE
  • monitoring the progress of such a disease e.g., monitoring the progress of such a disease
  • assessing the efficacy of a treatment for the disease identifying patients suitable for a particular treatment, and/or predicting disease attack in a subject.
  • a disease associated with the contact activation system based on the level of a biomarker set in a biological sample obtained from a subject.
  • the level of the biomarker as measured using any of the methods described herein, can be relied on to evaluate whether a subject (e.g., a human patient) from whom the biological sample is obtained, has or is at risk for a disease associated with the contact activation system, such as a disease associated with plasma kallikrein, e.g., HAE or autoimmune disease such as RA, UC, and Crohn's disease.
  • the level of the biomarker can then be compared with a reference sample or a control sample to determine a value indicating the amount of the RNA in the sample.
  • a value for a biomarker is obtained by comparing the level of a RNA in a sample to the level of another RNA (e.g., an internal control or internal standard) in the sample.
  • a biomarker value may be a normalized value over the internal control or internal standard.
  • the value of the biomarker can be compared to a reference value to determine whether the subject has or is at risk for the disease associated with the contact system.
  • the reference value may represent the level of the corresponding biomarker in subjects (e.g., human subjects) free of the target disease.
  • the subject can be identified as having or at risk for a disease associated with the contact activation system. In some embodiments, if the level or value of the biomarker is lower than a reference level or value, the subject can be identified as having or at risk for a disease associated with the contact activation system.
  • the level of the biomarker can be compared to a predetermined threshold for the RNA biomarker, a deviation from which may indicate the subject has a disease associated with the contact system.
  • the predetermined threshold may represent the value of the biomarker that distinguishes the level of the biomarker in patients having the target disease from the level of the biomarker in patients free of the target disease.
  • the biomarker set includes more than one RNA biomarkers that are differentially present (elevated and/or reduced) in a subject having or being at risk of having the disease as relative to healthy subjects.
  • the biomarker set includes at least one RNA biomarker that has an elevated level in a subject having or being at risk of having the disease and at least one RNA biomarker that has a reduced level in the subject having or at risk for the disease. Examples of the “elevated” and “reduced” RNA biomarkers are listed in Table 1.
  • the biomarker set includes more than one RNA, for each of which an elevated level indicates the subject has or is at risk of having the disease.
  • the biomarker set includes more than one RNA, for each of which a reduced level indicates the subject has or is at risk of having the disease.
  • control sample or reference sample is a biological sample obtained from a healthy individual. In some embodiments, the control sample or reference sample contains a known amount of the RNA to be assessed. In some embodiments, the control sample or reference sample is a biological sample obtained from a control subject.
  • control subject may be a healthy subject or healthy individual, that is apparently free of the target disease (e.g., a disease associated with the contact system) at the time the level of the RNA(s) is measured or has no history of the disease.
  • target disease e.g., a disease associated with the contact system
  • control subject encompasses an individual subject or a group of subjects having similar characteristics, for example, a group of healthy subjects having certain features matching those of the candidate subject, e.g., age, gender, ethnic group, etc.
  • the level of a biomarker in a control subject is used to establish a reference value (e.g., the average level of the biomarker in a control subject, which includes a group of subjects) that may be compared to the level of the biomarker in a candidate or test subject.
  • a reference value e.g., the average level of the biomarker in a control subject, which includes a group of subjects
  • the control level refers to the level of a RNA biomarker set as described herein in a control subject.
  • the control level can be a predetermined level or threshold.
  • Such a predetermined level can represent the level of the RNA in a population of subjects that do not have or are not at risk for the target disease (e.g., the average level in the population of healthy subjects). It can also represent the level of the RNA in a population of subjects that have the target disease.
  • the predetermined level can take a variety of forms. For example, it can be single cut-off value, such as a median or mean. In some embodiments, such a predetermined level can be established based upon comparative groups, such as where one defined group is known to have a target disease and another defined group is known to not have the target disease. Alternatively, the predetermined level can be a range, for example, a range representing the levels of the RNA in a control population.
  • control level as described herein can be determined by routine technology.
  • the control level can be obtained by performing a conventional method (e.g., the same assay for obtaining the level of the RNA a test sample as described herein) on a control sample as also described herein.
  • levels of the RNA can be obtained from members of a control population and the results can be analyzed by, e.g., a computational program, to obtain the control level (a predetermined level) that represents the level of the RNA in the control population.
  • the candidate subject By comparing the level of a biomarker in a sample obtained from a candidate subject to the reference value as described herein, it can be determined as to whether the candidate subject has or is at risk for a disease associated with the contact system (e.g., HAE). For example, if the level of biomarker(s) in a sample of the candidate subject deviates from the reference value (e.g., increased as compared to the reference value), the candidate subject might be identified as having or at risk for the disease.
  • the reference value represents the value range of the level of the biomarker in a population of subjects that have the target disease
  • the value of biomarker in a sample of a candidate falling in the range indicates that the candidate subject has or is at risk for the target disease.
  • an elevated level or “a level above a reference value” means that the level of the biomarker is higher than a reference value, such as a pre-determined threshold of a level the biomarker in a control sample. Control levels are described in detail herein.
  • An elevated level of a biomarker includes a level of the biomarker that is, for example, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500% or more above a reference value.
  • the level of the biomarker in the test sample is at least 1.1., 1.2, 1.3, 1.4, 15, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5, 6, 7, 8, 9, 10, 50, 100, 150, 200, 300, 400, 500, 1000, 10000-fold or higher than the level of the biomarker in a reference sample.
  • a decreased level or “a level below a reference value” means that the level of the biomarker is lower than a reference value, such as a pre-determined threshold of the biomarker in a control sample. Control levels are described in detail herein.
  • a decreased level of the biomarker includes a level of the biomarker that is, for example, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500% or more lower than a reference value.
  • the level of the biomarker in the test sample is at least 1.1., 1.2, 1.3, 1.4, 15, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5, 6, 7, 8, 9, 10, 50, 100, 150, 200, 300, 400, 500, 1000, 10000-fold or lower than the level of the biomarker in a reference sample.
  • the candidate subject is a human patient having a symptom of a disease associated with the contact activation system, such as a pKal-mediated disorder, e.g., HAE or an autoimmune disease such as RA, UC, and Crohn's disease.
  • a pKal-mediated disorder e.g., HAE or an autoimmune disease such as RA, UC, and Crohn's disease.
  • the subject has edema, swelling wherein said swelling is completely or predominantly peripheral; hives; redness, pain, and swelling in the absence of evidence of infection; non-histamine-mediated edema, recurrent attacks of swelling, or a combination thereof.
  • the subject has no symptom of a pKal-mediated disorder at the time the sample is collected, has no history of a symptom of a pKal-mediated disorder, or no history of a pKal-mediated disorder such as HAE.
  • the subject is resistant to an anti-histamine therapy, a corticosteroid therapy, or both.
  • a subject identified in the methods described herein may be subject to a suitable treatment, such as treatment with a pKal inhibitor, as described herein.
  • the assay methods and kits described herein also can be applied for evaluation of the efficacy of a treatment for a disease associated with the contact system, such as those described herein, given the correlation between the level of the biomarkers and such diseases.
  • multiple biological samples e.g., blood or plasma samples
  • the levels of a biomarker can be measured by any of the assay methods as described herein and values (e.g., amounts) of a biomarker can be determined accordingly.
  • an elevated level of a biomarker indicates that a subject has a target disease and the level of the biomarker decreases after the treatment or over the course of the treatment (the level of the biomarker in a later collected sample as compared to that in an earlier collected sample), it indicates that the treatment is effective.
  • a reduced level of a biomarker indicates that a subject has a target disease and the level of the biomarker increases after the treatment or over the course of the treatment (the level of the biomarker in a later collected sample as compared to that in an earlier collected sample), it indicates that the treatment is effective.
  • the treatment involves an effective amount of a therapeutic agent, such as a plasma kallikrein inhibitor, a bradykinin B2 receptor antagonist, or a C1 esterase inhibitor (C1-INH).
  • a therapeutic agent such as a plasma kallikrein inhibitor, a bradykinin B2 receptor antagonist, or a C1 esterase inhibitor (C1-INH).
  • the therapeutic agents include, but not limited to, lanadelumab, ecallantide, icatibant, and human plasma-derived C1-INH.
  • a higher dose and/or frequency of dosage of the therapeutic agent are administered to the subject identified.
  • the dosage or frequency of dosage of the therapeutic agent is maintained, lowered, or ceased in a subject identified as responsive to the treatment or not in need of further treatment.
  • a different treatment can be applied to the subject who is found as not responsive to the first treatment.
  • the values of a biomarker or biomarker set can also be relied on to identify that a disorder is associated with the contact system or that the disorder may be treatable, for example by a pKal inhibitor.
  • the level of a biomarker in a sample collected from a subject e.g., a blood sample or a plasma sample
  • a suitable method e.g., those described herein such as mass spectrometry, chromatography, immunoassays. If the level of the biomarker deviates from the reference value (e.g., elevated or decreased), it indicates that a pKal inhibitor may be effective in treating the disease.
  • the method can further comprise administering to the subject having the disease an effective amount of a pKal inhibitor, such as an anti-pKal antibody or an inhibitory peptide (e.g., lanadelumab, ecallantide, etc.); a bradykinin 2 receptor inhibitor (e.g., icatibant); and/or a C1-INH (e.g. human plasma-derived C1-INH).
  • a pKal inhibitor such as an anti-pKal antibody or an inhibitory peptide (e.g., lanadelumab, ecallantide, etc.); a bradykinin 2 receptor inhibitor (e.g., icatibant); and/or a C1-INH (e.g. human plasma-derived C1-INH).
  • HAE may be in the quiescent state (basal state), during which the subject does not experience symptoms of the disease.
  • HAE attacks are typically recurrent episodes in which the subject may experience pain and swelling, for example in the hands, feet, face, gastrointestinal tract, genitals, and larynx (throat) that can last from two to five days.
  • the level of one or more biomarker is indicative of whether the subject will experience, is experiencing, or will soon experience an HAE attack.
  • the methods involve comparing the level of a biomarker in a sample obtained from a subjecting having HAE to the level of the biomarker in a sample from the same subject, for example a sample obtained from the same subject at basal state or a sample obtained from the same subject during a HAE attack.
  • HAE attacks are typically recurrent episodes during which the subject may experience symptoms such as pain and swelling.
  • the level of one or more biomarker is indicative of whether the subject is at risk of having an HAE attack.
  • the methods involve comparing the level of a biomarker in a sample obtained from a subjecting having HAE to the level of the biomarker in a sample from the same subject, for example a sample obtained from the same subject at basal state or a sample obtained from the same subject during a HAE attack.
  • the level of the biomarker in another sample from the subject may indicated that the subject is an increase (or a decrease) in the level of a biomarker associated with an HAE attack as compared to at risk of having an HAE attack.
  • the methods involve comparing the level of a biomarker in a sample obtained from a subjecting having HAE to the level of the biomarker in a control or reference sample.
  • the level of the biomarker in the control or reference sample represents the level of the biomarker that indicates a HAE attack state.
  • a level of the biomarker in a sample obtained from a subjecting having HAE that is similar to the level of the biomarker in a reference that represents an HAE attack state may indicate that the subject is at risk of having a HAE attack.
  • the level of the biomarker in the control or reference sample represents the level of the biomarker that indicates HAE in the basal state.
  • a level of the biomarker in a sample obtained from a subjecting having HAE that deviates (is elevated or reduced) to the level of the biomarker in a reference that represents a HAE in the basal state may indicate that the subject is at risk of having a HAE attack.
  • levels of any of the biomarker set described herein may be used for research purposes. Although many diseases associated with the contact activation system have been identified, it is possible that other diseases are mediated by similar mechanisms or involve similar components. In some embodiments, the methods described herein may be used to identify a disease as being associated with the contact activation system or with components of the contact activation system. In some embodiments, the methods described herein may be used to study mechanisms (e.g., the discovery of novel biological pathways or processes involved in disease development) or progression of a disease.
  • the levels of biomarker sets may be relied on in the development of new therapeutics for a disease associated with the contact activation system.
  • the levels of a biomarker set may be measured in samples obtained from a subject having been administered a new therapy (e.g., a clinical trial).
  • the level of the biomarker set may indicate the efficacy of the new therapeutic or the progression of the disease in the subject prior to, during, or after the new therapy.
  • kits and detecting devices for use in measuring the level of a biomarker set as described herein.
  • a kit or detecting device can comprise binding agents that specifically bind to the RNA biomarkers, such as those listed in Table 1.
  • a kit or detecting device may comprise at least two binding agents that are specific to two different RNA biomarkers selected from Table 1.
  • the kit or detecting device comprises binding agents specific to all members of the RNA biomarker set described herein.
  • the binding agent is an oligonucleotide, as described herein, which is complementary to a RNA biomarker.
  • the binding agent comprises a pair of oligonucleotides (e.g., a primer pair) each of which binds (hybridizes) to a specific nucleotide sequence in the RNA biomarker.
  • the pair of oligonucleotides hybridizes to the RNA biomarker and allow for the amplification of the RNA biomarker, when subjected to methods such as polymerase chain reaction.
  • the amplified product may be directly detected, for example by detecting a dye, fluorophore or other indicator agent that is intercalated into the nucleic acid during the polymerase chain reaction.
  • at least one of the oligonucleotides is conjugated to a label, which can be detected.
  • the RNA biomarker is measured using a nucleic acid hybridization method.
  • the binding agent is an oligonucleotide that is complementary to a RNA biomarker and hybridizes to the RNA biomarker, if present in a sample (e.g., a biological sample or a sample from polymerase chain reaction).
  • the oligonucleotide is conjugated to a label, such as any of the labels described herein, which can be detected.
  • hybridization methods include Northern blotting, Southern blotting, and microarrays.
  • one or more of the binding agents is a nucleic-acid binding protein that specifically binds to a RNA of the biomarker set.
  • the binding agent is directly detected or may be conjugated to a tag that can be identified and, directly or indirectly.
  • the kit or device further includes a support member, as described herein.
  • a support member e.g., a membrane, a bead, a slide, or a multi-well plate. Selection of an appropriate support member for the immunoassay will depend on various factor such as the number of samples and method of detecting the signal released from label conjugated to the second agent.
  • the kit can also comprise one or more buffers as described herein but not limited to a coating buffer, a blocking buffer, a wash buffer, and/or a stopping buffer.
  • the kit can comprise instructions for use in accordance with any of the methods described herein.
  • the included instructions can comprise a description of how to use the components contained in the kit for measuring the level of RNAs of RNA biomarker set in a biological sample collected from a subject, such as a human patient.
  • the instructions relating to the use of the kit generally include information as to the amount of each component and suitable conditions for performing the assay methods described herein.
  • the components in the kits may be in unit doses, bulk packages (e.g., multi-dose packages), or sub-unit doses.
  • Instructions supplied in the kits of the present disclosure are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
  • the label or package insert indicates that the kit is used for evaluating the level of RNAs of a biomarker set. Instructions may be provided for practicing any of the methods described herein.
  • kits of this present disclosure are in suitable packaging.
  • suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like.
  • packages for use in combination with a specific device such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump.
  • a kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • Kits may optionally provide additional components such as interpretive information, such as a control and/or standard or reference sample.
  • the kit comprises a container and a label or package insert(s) on or associated with the container.
  • the present disclosure provides articles of manufacture comprising contents of the kits described above.
  • a subject at risk for or suffering from a disease associated with the contact activation system, as identified using the methods described herein, may be treated with any appropriate therapeutic agent.
  • provided methods include selecting a treatment for a subject based on the output of the described method, e.g., measuring the level of a biomarker set.
  • the methods described herein provide methods of identifying a subject as a candidate for preventative (prophylactic) treatment.
  • a “preventative” treatment includes any therapy or treatment regimen that aims to prevent or reduce the incidence of a disease (e.g., HAE attack).
  • the methods further comprise administering a preventative treatment to the subject.
  • Any of the therapeutic agents described herein e.g., pKal inhibitors, such as lanadelumab).
  • the level of a RNA biomarker set in a sample obtained from a subject indicates that the patient has or is at risk of having HAE (e.g., by comparing the level of the RNA biomarker to the level in a reference or control sample). Any subject having or at risk of having HAE may be administered a prophylactic treatment. Selection of an appropriate therapeutic agent and administration regimen for a preventative treatment will be evident to one of ordinary skill in the art.
  • the method comprises one or both of selecting or administering a therapeutic agent, e.g., a kallikrein inhibitor, a bradykinin B2 receptor inhibitor, and/or a C1 esterase inhibitor, for administration to the subject based on the output of the assay, e.g., biomarker detection.
  • a therapeutic agent e.g., a kallikrein inhibitor, a bradykinin B2 receptor inhibitor, and/or a C1 esterase inhibitor
  • the therapeutic agent is administered one or more times to the subject.
  • a plasma kallikrein inhibitor is administered to a subject.
  • kallikrein inhibitor is a peptide, a small molecule inhibitor, a kallikrein antibody, or a fragment thereof.
  • an antagonist of bradykinin B2 receptor is administered to a subject.
  • a C1-INH is administered to a subject.
  • the therapeutic agent e.g., kallikrein inhibitor, bradykinin B2 receptor inhibitor, and/or C1-INH
  • Combination therapy e.g., with one or more of a kallikrein inhibitor, bradykinin B2 receptor antagonist, or C
  • 1-INH replacement agent e.g., with one or more of a kallikrein inhibitor, bradykinin B2 receptor antagonist or C1-INH replacement agent and another therapy
  • the first agent may be administered before or after the administration of the other therapy.
  • the first agent and another therapy are administered concurrently, or in close temporal proximity (e.g., a short time interval between the injections, such as during the same treatment session).
  • the first agent and the other therapy may also be administered at greater temporal intervals.
  • Plasma kallikrein binding agents e.g., binding proteins, e.g., polypeptides, e.g., inhibitory polypeptides, e.g., antibodies, e.g., inhibitory antibodies, or other binding agents, e.g., small molecules
  • the disease or condition that involves plasma kallikrein activity is hereditary angioedema (HAE).
  • a plasma kallikrein binding agent such as a plasma kallikrein inhibitor is administered to a subject at risk or suffering from a disease associated with the contact activation system.
  • a number of useful protein inhibitors of kallikrein, either tissue and/or plasma kallikrein, include a Kunitz domain.
  • a “Kunitz domain” is a polypeptide domain having at least 51 amino acids and containing at least two, and preferably three, disulfides.
  • the domain is folded such that the first and sixth cysteines, the second and fourth, and the third and fifth cysteines form disulfide bonds (e.g., in a Kunitz domain having 58 amino acids, cysteines can be present at positions corresponding to amino acids 5, 14, 30, 38, 51, and 55, according to the number of the BPTI homologous sequences provided below, and disulfides can form between the cysteines at position 5 and 55, 14 and 38, and 30 and 51), or, if two disulfides are present, they can form between a corresponding subset of cysteines thereof.
  • disulfides can form between the cysteines at position 5 and 55, 14 and 38, and 30 and 51
  • the spacing between respective cysteines can be within 7, 5, 4, 3, 2, 1 or 0 amino acids of the following spacing between positions corresponding to: 5 to 55, 14 to 38, and 30 to 51, according to the numbering of the BPTI sequence provided below.
  • the BPTI sequence can be used as a reference to refer to specific positions in any generic Kunitz domain. Comparison of a Kunitz domain of interest to BPTI can be performed by identifying the best fit alignment in which the number of aligned cysteines in maximized.
  • the 3D structure (at high resolution) of the Kunitz domain of BPTI is known.
  • One of the X-ray structures is deposited in the Brookhaven Protein Data Bank as “6PTI”.
  • the 3D structure of some BPTI homologues (Eigenbrot et al., Protein Engineering (1990) 3(7):591-598; Hynes et al., Biochemistry (1990) 29:10018-10022) are known.
  • At least eighty one Kunitz domain sequences are known.
  • Known human homologues include three Kunitz domains of LACI also known as tissue factor pathway inhibitor (TFPI) (Wun et al., J. Biol. Chem .
  • LACI is a human serum phosphoglycoprotein with a molecular weight of 39 kDa (amino acid sequence in Table 2) containing three Kunitz domains.
  • LACI-K1 The Kunitz domains above are referred to as LACI-K1 (residues 50 to 107), LACI-K2 (residues 121 to 178), and LACI-K3 (213 to 270).
  • the cDNA sequence of LACI is reported in Wun et al. ( J. Biol. Chem . (1988) 263(13):6001-6004). Girard et al. ( Nature (1989) 338:518-20) reports mutational studies in which the P1 residues of each of the three Kunitz domains were altered.
  • LACI-K1 inhibits Factor VIIa (F.VIIa) when F.VIIa is complexed to tissue factor and LACI-K2 inhibits Factor Xa.
  • Proteins Containing Exemplary Kunitz Domains include the following, with SWISS-PROT Accession Numbers in parentheses:
  • a variety of methods can be used to identify a Kunitz domain from a sequence database.
  • a known amino acid sequence of a Kunitz domain, a consensus sequence, or a motif e.g., the ProSite Motif
  • GenBank sequence databases National Center for Biotechnology Information, National Institutes of Health, Bethesda MD
  • Pfam database of HMMs Hidden Markov Models
  • Pfam Accession Number PF00014 of Pfam Release 9 provides numerous Kunitz domains and an HMM for identify Kunitz domains.
  • the SMART database (Simple Modular Architecture Research Tool, EMBL, Heidelberg, DE) of HMMs as described in Schultz et al. Proc. Natl. Acad. Sci. USA (1998) 95:5857 and Schultz et al. Nucl. Acids Res (2000) 28:231.
  • the SMART database contains domains identified by profiling with the hidden Markov models of the HMMer2 search program (R. Durbin et al. (1998) Biological sequence analysis: probabilistic models of proteins and nucleic acids . Cambridge University Press). The database also is annotated and monitored.
  • the ProDom protein domain database consists of an automatic compilation of homologous domains (Corpet et al. Nucl. Acids Res .
  • Kunitz domains interact with target protease using, primarily, amino acids in two loop regions (“binding loops”).
  • the first loop region is between about residues corresponding to amino acids 13-20 of BPTI.
  • the second loop region is between about residues corresponding to amino acids 31-39 of BPTI.
  • An exemplary library of Kunitz domains varies one or more amino acid positions in the first and/or second loop regions.
  • Particularly useful positions to vary, when screening for Kunitz domains that interact with kallikrein or when selecting for improved affinity variants include: positions 13, 15, 16, 17, 18, 19, 31, 32, 34, and 39 with respect to the sequence of BPTI. At least some of these positions are expected to be in close contact with the target protease. It is also useful to vary other positions, e.g., positions that are adjacent to the aforementioned positions in the three-dimensional structure.
  • the “framework region” of a Kunitz domain is defined as those residues that are a part of the Kunitz domain, but specifically excluding residues in the first and second binding loops regions, i.e., about residues corresponding to amino acids 13-20 of BPTI and 31-39 of BPTI. Conversely, residues that are not in the binding loop may tolerate a wider range of amino acid substitution (e.g., conservative and/or non-conservative substitutions).
  • these Kunitz domains are variant forms of the looped structure including Kunitz domain 1 of human lipoprotein-associated coagulation inhibitor (LACI) protein.
  • LACI contains three internal, well-defined, peptide loop structures that are paradigm Kunitz domains (Girard, T. et al., Nature (1989) 338:518-520). Variants of Kunitz domain 1 of LACI described herein have been screened, isolated and bind kallikrein with enhanced affinity and specificity (see, for example, U.S. Pat. Nos. 5,795,865 and 6,057,287). These methods can also be applied to other Kunitz domain frameworks to obtain other Kunitz domains that interact with kallikrein, e.g., plasma kallikrein.
  • Useful modulators of kallikrein function typically bind and/or inhibit kallikrein, as determined using kallikrein binding and inhibition assays.
  • the plasma kallikrein inhibitor binds to the active form of plasma kallikrein.
  • the plasma kallikrein inhibitor binds to and inhibits plasma kallikrein, e.g., human plasma kallikrein and/or murine kallikrein.
  • Exemplary polypeptide plasma kallikrein agents are disclosed in U.S. Pat. Nos. 5,795,865, 5,994,125, 6,057,287, 6,333,402, 7,628,983, and 8,283,321, 7,064,107, 7,276,480, 7,851,442, 8,124,586, 7,811,991, and U.S. Publication No. 20110086801, the entire contents of each of which is incorporated herein by reference.
  • the plasma kallikrein inhibitor is an inhibitory polypeptide or peptide.
  • the inhibitory peptide is ecallantide (also referred to as DX-88 or KALBITOR®; SEQ ID NO:3).
  • the kallikrein inhibitor comprises or consists of an about 58-amino acid sequence of amino acids 3-60 of SEQ ID NO:3 or the DX-88 polypeptide having the 60-amino acid sequence of SEQ ID NO:3.
  • Plasma kallikrein inhibitor can be full-length antibodies (e.g., an IgG (e.g., an IgG1, IgG2, IgG3, IgG4), IgM, IgA (e.g., IgA1, IgA2), IgD, and IgE) or can include only an antigen-binding fragment (e.g., a Fab, F(ab′)2 or scFv fragment).
  • the binding protein can include two heavy chain immunoglobulins and two light chain immunoglobulins, or can be a single chain antibody.
  • Plasma kallikrein inhibitor can be recombinant proteins such as humanized, CDR grafted, chimeric, deimmunized, or in vitro generated antibodies, and may optionally include constant regions derived from human germline immunoglobulin sequences.
  • the plasma kallikrein inhibitor is a monoclonal antibody.
  • the kallikrein binding protein is an antibody (e.g., a human antibody) having the light and/or heavy chains of antibodies selected from the group consisting of M162-A04, M160-G12, M142-H08, X63-G06, X101-A01 (also referred to as DX-2922), X81-B01, X67-D03, X67-G04, X81-B01, X67-D03, X67-G04, X115-B07, X115-D05, X115-E09, X115-H06, X115-A03, X115-D01, X115-F02, X124-G01 (also referred to herein as DX-2930 or lanadelumab), X115-G04, M29-D
  • the plasma kallikrein binding protein competes with or binds the same epitope as M162-A04, M160-G12, M142-H08, X63-G06, X101-A01 (also referred to herein as DX-2922), X81-B01, X67-D03, X67-G04, X81-B01, X67-D03, X67-G04, X115-B07, X115-D05, X115-E09, X115-H06, X115-A03, X115-D01, X115-F02, X124-G01, X115-G04, M29-D09, M145-D11, M06-D09 and M35-G04.
  • the plasma kallikrein binding protein is lanadelumab. See US Publication No. 20110200611 and US Publication No. 20120201756, which are incorporated by reference herein.
  • lanadelumab An example of a plasma kallikrein inhibitory antibody is lanadelumab.
  • the amino acid sequences of the heavy chain and light chain variable regions of lanadelumab are provided below with the CDR regions identified in boldface and underlined.
  • Lanadelumab heavy chain variable region sequence (SEQ ID NO: 4) EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYIMMWVRQA PGKGLEWVSG IYSSGGITVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR IGVPRRDEFD IWGQGTMVTV SS
  • Lanadelumab light chain variable region sequence (SEQ ID NO: 5) DIQMTQSPS TLSASVGDRV TITCRASQSI SSWLAWYQQK PGKAPKLLIY KASTLESGVP SRFSGSGSGT EFTLTISSLQ PDDFATYYCQ QYNTYWTFGQ GTKVEI
  • a plasma kallikrein inhibitor can have about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity to a plasma kallikrein inhibitor described herein. In some embodiments, a plasma kallikrein inhibitor can have about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity in the HC and/or LC framework regions (e.g., HC and/or LC FR 1, 2, 3, and/or 4) to a plasma kallikrein inhibitor described herein.
  • HC and/or LC framework regions e.g., HC and/or LC FR 1, 2, 3, and/or 4
  • a plasma kallikrein inhibitor can have about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity in the HC and/or LC CDRs (e.g., HC and/or LC CDR1, 2, and/or 3) to a plasma kallikrein inhibitor described herein.
  • a plasma kallikrein inhibitor can have about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity in the constant region (e.g., CH1, CH2, CH3, and/or CL1) to a plasma kallikrein inhibitor described herein.
  • a small molecule binds and inhibits the active form of plasma kallikrein.
  • a bradykinin B2 receptor inhibitor e.g., antagonist
  • exemplary bradykinin B2 receptor antagonists include icatibant (Firazyr®), which is a peptidomimetic drug containing 10 amino acids which block binding of native bradykinin to the bradykinin B2 receptor.
  • a C1 esterase inhibitor such as a replacement C1-INH agent is administered to a subject.
  • C1-INH replacement agents are publicly available and include, for example, human plasma-derived C1-INH, e.g. Berinert® and CINRYZE®.
  • RNA transcripts of mitochondria-encoded transcripts for Mitochondrial Encoded NADH:Ubiquinnone Oxidoreductase Core Subunit 3 (MT-ND3) and Mitochondrial Encoded Cytochrome C Oxidase III were higher in samples from patients having HAE (during attack or quiescence) as compared to in samples from healthy individuals in the initial RNASeq as well as by RT-qPCR analysis. These results indicated that these RNA can be used as biomarkers to distinguish between samples from patients with HAE from healthy individuals.
  • microRNAs were found to be differentially present in samples obtained from HAE patients and healthy individuals. For example, hsa-miR-423-3p, hsa-miR-1307-3p, hsa-miR-355-3p, and hsa-miR-485-5p were elevated in samples from HAE patients.
  • Several microRNAs were also found at reduced levels in samples from HAE patients, including hsa-miR-16-5p, hsa-miR-19a-3p, hsa-miR-20a-5p, hsa-miR-17-5p, and hsa-miR-885-5p.
  • the analysis also identified several microRNAs that were reduced in samples from HAE patients during an attack as compared to at basal state, for example, has-miR-1307-3p, hsa-miR-335-3p, and hsa-miR-485-5p ( FIG. 2 , panel C).
  • RNAs identified herein may be used as a biomarker (individually or in combination (biomarker set)) for diseases associated with the contact activation system, for example in methods for identifying patients who are at risk of a disease associated with the contact activation system (e.g., HAE), selecting a candidate for treatment, monitoring disease progression or disease state, assessing the efficacy of a treatment against a disease, determining a course of treatment, identifying whether a disease or disorder is associated with the contact activation system, and/or for research purposes, including, e.g., studying the mechanism of a disease, which may be relied upon for the development of new therapies.
  • biomarker individually or in combination (biomarker set)
  • biomarker set for diseases associated with the contact activation system, for example in methods for identifying patients who are at risk of a disease associated with the contact activation system (e.g., HAE), selecting a candidate for treatment, monitoring disease progression or disease state, assessing the efficacy of a treatment against a disease,
  • the present disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
  • any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
  • elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the present disclosure, or aspects of the present disclosure, is/are referred to as comprising particular elements and/or features, certain embodiments of the present disclosure or aspects of the present disclosure consist, or consist essentially of, such elements and/or features.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US16/333,177 2016-09-16 2017-09-15 RNA biomarkers for hereditary angioedema Active 2038-12-10 US11884979B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/333,177 US11884979B2 (en) 2016-09-16 2017-09-15 RNA biomarkers for hereditary angioedema

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395811P 2016-09-16 2016-09-16
PCT/US2017/051772 WO2018053260A1 (en) 2016-09-16 2017-09-15 Rna biomarkers for hereditary angioedema
US16/333,177 US11884979B2 (en) 2016-09-16 2017-09-15 RNA biomarkers for hereditary angioedema

Publications (2)

Publication Number Publication Date
US20190241961A1 US20190241961A1 (en) 2019-08-08
US11884979B2 true US11884979B2 (en) 2024-01-30

Family

ID=60117738

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/333,177 Active 2038-12-10 US11884979B2 (en) 2016-09-16 2017-09-15 RNA biomarkers for hereditary angioedema

Country Status (13)

Country Link
US (1) US11884979B2 (zh)
EP (1) EP3513188A1 (zh)
JP (2) JP7319916B2 (zh)
KR (2) KR20230125104A (zh)
CN (2) CN109716129B (zh)
AU (2) AU2017325999C1 (zh)
BR (1) BR112019005172A2 (zh)
CA (1) CA3036979A1 (zh)
CO (1) CO2019002608A2 (zh)
EA (1) EA201990730A1 (zh)
IL (1) IL265200A (zh)
MX (1) MX2019002929A (zh)
WO (1) WO2018053260A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3513197A1 (en) 2016-09-16 2019-07-24 Dyax Corp. Metabolite biomarkers for diseases associated with the contact activation system
KR102513485B1 (ko) 2016-09-16 2023-03-23 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
CN111184734B (zh) * 2020-03-05 2021-04-27 北京市心肺血管疾病研究所 miRNA在治疗心肌肥厚中的应用
CN111518883B (zh) * 2020-04-02 2022-12-30 深圳大学 一种用于冠心病诊断的血浆miRNA标志物及其应用
CN113311056B (zh) * 2021-05-10 2022-06-21 中国医学科学院北京协和医院 用于遗传性血管水肿的标志物及其应用
CN113736896A (zh) * 2021-09-09 2021-12-03 中国医学科学院北京协和医院 用于预测遗传性血管性水肿发作的标志物及其应用

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653080A (zh) 2002-03-07 2005-08-10 路德维格癌症研究院 淋巴管和血管的内皮细胞基因
US20060275313A1 (en) 2002-11-29 2006-12-07 Clark Georgina J Therapeutic and diagnostic agents
US20070021589A1 (en) 2003-01-13 2007-01-25 Greg Collier Obesity-related genes
US20070192882A1 (en) 2004-05-18 2007-08-16 Georg Dewald Hereditary angioedema type III
US20090064350A1 (en) 2005-11-23 2009-03-05 Georg Dewald Detection and treatment of drug associated angioedema
CN101495498A (zh) 2005-02-07 2009-07-29 基因信息公司 轻度骨关节炎生物标志物及其用途
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20110151430A1 (en) 2007-09-06 2011-06-23 University Of Massachusetts VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION
WO2012145363A1 (en) 2011-04-18 2012-10-26 Diamir, Llc METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)
US20130053275A1 (en) 2010-04-29 2013-02-28 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US20130102485A1 (en) 2011-10-19 2013-04-25 Inhan Lee Method of Determining a Diseased State in a Subject
US20130259839A1 (en) 2007-03-27 2013-10-03 Ranit Aharonov Gene expression signature for classification of tissue of origin of tumor samples
US20130337479A1 (en) 2010-12-22 2013-12-19 Mcbi Inc. Biomarker for cognitive dysfunction diseases, and method for detection of cognitive dysfunction diseases using the biomarker
WO2014036429A1 (en) 2012-08-31 2014-03-06 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
US20140162888A1 (en) 2010-04-06 2014-06-12 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20140213631A1 (en) 2011-06-10 2014-07-31 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
WO2015031679A2 (en) 2013-08-28 2015-03-05 Isis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
WO2015037656A1 (ja) 2013-09-11 2015-03-19 国立大学法人北海道大学 オートファジーを調節するマイクロｒｎａ
WO2015066611A2 (en) 2013-11-01 2015-05-07 The Trustees Of Columbia University In The City Of New York Microrna profiles in heart failure: methods and systems for detection and use
CN104651513A (zh) 2015-02-15 2015-05-27 青岛大学附属医院 一种痛风血清miRNAs生物标志物及其表达量的检测方法
WO2015179909A1 (en) 2014-05-26 2015-12-03 The University Of Melbourne Mirna biomarkers of alzheimer's disease
WO2015182781A1 (ja) 2014-05-30 2015-12-03 東レ株式会社 膵臓がんの検出キット又はデバイス及び検出方法
WO2016020625A1 (fr) 2014-08-07 2016-02-11 Galderma Research & Development Microarns caractérisant la rosacée et leurs utilisations
WO2016020626A1 (fr) 2014-08-07 2016-02-11 Galderma Research & Development microARNs CARACTÉRISANT L'ACNÉ ET LEURS UTILISATIONS
WO2016023077A1 (en) 2014-08-15 2016-02-18 Griffith University Biological markers
CN105527419A (zh) 2014-12-11 2016-04-27 北京新华联协和药业有限责任公司 遗传性血管水肿的检测试剂盒及其制备方法
WO2016109774A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JP2016144439A (ja) 2015-01-30 2016-08-12 ロート製薬株式会社 細胞の品質を評価する方法、及び細胞の品質判定キット
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
WO2016139092A1 (en) 2015-03-04 2016-09-09 Hummingbird Diagnostics Gmbh Signature of health
US20170002094A1 (en) 2014-01-21 2017-01-05 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795865A (en) 1994-01-11 1998-08-18 Dyax Corp. Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente

Patent Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653080A (zh) 2002-03-07 2005-08-10 路德维格癌症研究院 淋巴管和血管的内皮细胞基因
US20060275313A1 (en) 2002-11-29 2006-12-07 Clark Georgina J Therapeutic and diagnostic agents
US20070021589A1 (en) 2003-01-13 2007-01-25 Greg Collier Obesity-related genes
US20070192882A1 (en) 2004-05-18 2007-08-16 Georg Dewald Hereditary angioedema type III
CN101495498A (zh) 2005-02-07 2009-07-29 基因信息公司 轻度骨关节炎生物标志物及其用途
US20090064350A1 (en) 2005-11-23 2009-03-05 Georg Dewald Detection and treatment of drug associated angioedema
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20130259839A1 (en) 2007-03-27 2013-10-03 Ranit Aharonov Gene expression signature for classification of tissue of origin of tumor samples
US20110151430A1 (en) 2007-09-06 2011-06-23 University Of Massachusetts VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION
US20140162888A1 (en) 2010-04-06 2014-06-12 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20130053275A1 (en) 2010-04-29 2013-02-28 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US20130337479A1 (en) 2010-12-22 2013-12-19 Mcbi Inc. Biomarker for cognitive dysfunction diseases, and method for detection of cognitive dysfunction diseases using the biomarker
WO2012145363A1 (en) 2011-04-18 2012-10-26 Diamir, Llc METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)
JP2014513528A (ja) 2011-04-18 2014-06-05 ディアミール，エルエルシー 軽度認知機能障害（ＭＣＩ）およびアルツハイマー病（ＡＤ）の早期検出ならびにモニタリングのために体液からのｍｉＲＮＡを使用する方法
US20140213631A1 (en) 2011-06-10 2014-07-31 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US20130102485A1 (en) 2011-10-19 2013-04-25 Inhan Lee Method of Determining a Diseased State in a Subject
WO2014036429A1 (en) 2012-08-31 2014-03-06 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
CN105517556A (zh) 2013-08-28 2016-04-20 Ionis制药公司 前激肽释放酶(pkk)表达的调节
WO2015031679A2 (en) 2013-08-28 2015-03-05 Isis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
WO2015037656A1 (ja) 2013-09-11 2015-03-19 国立大学法人北海道大学 オートファジーを調節するマイクロｒｎａ
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
WO2015066611A2 (en) 2013-11-01 2015-05-07 The Trustees Of Columbia University In The City Of New York Microrna profiles in heart failure: methods and systems for detection and use
US20170002094A1 (en) 2014-01-21 2017-01-05 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015179909A1 (en) 2014-05-26 2015-12-03 The University Of Melbourne Mirna biomarkers of alzheimer's disease
WO2015182781A1 (ja) 2014-05-30 2015-12-03 東レ株式会社 膵臓がんの検出キット又はデバイス及び検出方法
WO2016020625A1 (fr) 2014-08-07 2016-02-11 Galderma Research & Development Microarns caractérisant la rosacée et leurs utilisations
WO2016020626A1 (fr) 2014-08-07 2016-02-11 Galderma Research & Development microARNs CARACTÉRISANT L'ACNÉ ET LEURS UTILISATIONS
WO2016023077A1 (en) 2014-08-15 2016-02-18 Griffith University Biological markers
CN105527419A (zh) 2014-12-11 2016-04-27 北京新华联协和药业有限责任公司 遗传性血管水肿的检测试剂盒及其制备方法
WO2016109774A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JP2016144439A (ja) 2015-01-30 2016-08-12 ロート製薬株式会社 細胞の品質を評価する方法、及び細胞の品質判定キット
CN104651513A (zh) 2015-02-15 2015-05-27 青岛大学附属医院 一种痛风血清miRNAs生物标志物及其表达量的检测方法
WO2016139092A1 (en) 2015-03-04 2016-09-09 Hummingbird Diagnostics Gmbh Signature of health

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
Buyantseva et al., Update on treatment of hereditary angioedema. Asian Pac J Allergy Immunol. Jun. 2012;30(2):89-98.
Cui et al. Cyclooxygenase-3 Gene Expression in Alzheimer's Hippocampus and in Stressed Human Neural Cells (2004) Neurochemical Research vol. 29, No. 9, 1731-1737 (Year: 2004). *
Fu et al. Relationship between mitochondrial cytochrome oxidase mRNA expression and maternal inheritance of asthma (2013) Natl Med J China vol. 93, No. 28, Abstract (Year: 2013). *
Gao et al. Journal of Allergy and Clinical Immunology, p. AB32. Abstract #117 (Year: 2014). *
Gao et al., Circulating Extracellular Micrornas in Hereditary Angioedema. J Allergy Clin Immunol. Feb. 2014;133(S2):AB32. Abstract 117. doi: 10.1016/j.jaci.2013.12.141.
Gao et al; J Allergy Clin Immunology, 2014, AB32 abstract 117. *
GeoPlatform Accession GPL15497, Applied Biosystems TaqMan Array Human MicroRNA Cards, Apr. 27, 2012, including full table listing, record obtained from https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL15497 on Jul. 29, 2021. (Year: 2012). *
Giavina-Bianchi et al., Brazilian Guidelines for Hereditary Angioedema Management—2017 Update Part 1: Definition, Classification and Diagnosis. Clinics (Sao Paulo). 2018;73:e310. doi: 10.6061/clinics/2018/e310. Epub May 3, 2018.
Ha et al. Interspecies Regulation of MicroRNAs and Their Targets (2008) Biochim Biophys Acta 1779(11): 735-742. (Year: 2008). *
Kelemen et al., Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. Clin Immunol. Mar. 2010;134(3):354-8. doi: 10.1016/j.clim.2009.11.002. Epub Nov. 27, 2009.
Kuśnierz-Cabala et al., Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis. Pancreatology. Jul.-Aug. 2015;15(4):344-51. doi: 10.1016/j.pan.2015.05.475. Epub Jun. 6, 2015.
Lopez-Lera et al. Orphanet Journal of Rare Diseases, 8:77; 12 pages (Year: 2013). *
López-Lera et al., Disease-modifying factors in hereditary angioedema: an RNA expression-based screening. Orphanet J Rare Dis. May 20, 2013;8:77. doi: 10.1186/1750-1172-8-77.
Lopez-Lera et al; Orphanet Journal of Rare Diseases, 8:77, 2013; pp. 1-12. *
McGee et al. Mitochondrial bioenergetics changes are induced by metabolic endotoxinaemia contributing to mitochondrial stress and dysfunction in human adipocytes (2011) Diabetologia 54:[Suppl1]S1-S542 (Year: 2011). *
Nagai et al. Changes in mitochondrial cytochrome c oxidase mRNA levels with cataract severity in lens epithelia of Japanese patients (2019) Molecular Medicine Reports 19:5464-5472. (Year: 2019). *
Oksuz et al. Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma (2016) J. Neurooncol. 126:271-278 (Year: 2016). *
PCT/US2017/051772, Dec. 7, 2017, Invitation to Pay Additional Fees.
PCT/US2017/051772, Feb. 5, 2018, International Search Report and Written Opinion.
PCT/US2017/051772, Mar. 28, 2019, International Preliminary Report on Patentability.
Wang et al., The Intersection of the Kallikrein Kinin System and Fibrinolysis Coagulation System—Contact System, the Myth and Application. Medical Recapitulate. May 20, 2015;21(10):1740-1742.
Xu et al., Pathogenic Mechanism of Hereditary Angioedema. Chinese Journal of Allergy and Clinical Immunology. Jun. 30, 2012;6(2):125-130.
Yu, et al. IgA nephropathy is associated with elevated urinary mitochondrial DNA copy numbers (2019) Nature Research, Scientific Reports 9:16068, 9 pages. (Year: 2019). *
Zhu et al., Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int J Gynecol Obstet. Jul. 2015;130(1):49-53. doi: 10.1016/j.ijgo.2015.01.010. Epub Mar. 23, 2015.

Also Published As

Publication number Publication date
KR20190045369A (ko) 2019-05-02
CN109716129B (zh) 2023-10-03
CA3036979A1 (en) 2018-03-22
CO2019002608A2 (es) 2019-03-29
KR102569559B1 (ko) 2023-08-23
AU2017325999C1 (en) 2024-03-07
NZ751439A (en) 2023-12-22
EP3513188A1 (en) 2019-07-24
US20190241961A1 (en) 2019-08-08
IL265200A (en) 2019-05-30
KR20230125104A (ko) 2023-08-28
AU2017325999A1 (en) 2019-03-28
JP2019528733A (ja) 2019-10-17
WO2018053260A1 (en) 2018-03-22
JP7319916B2 (ja) 2023-08-02
CN109716129A (zh) 2019-05-03
AU2024201287A1 (en) 2024-03-14
JP2023126649A (ja) 2023-09-07
AU2017325999B2 (en) 2023-11-30
BR112019005172A2 (pt) 2019-07-02
MX2019002929A (es) 2019-07-15
CN117187377A (zh) 2023-12-08
EA201990730A1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
JP7496380B2 (ja) ブラジキニン媒介障害の評価および治療
US11884979B2 (en) RNA biomarkers for hereditary angioedema
EP2946206B1 (en) Evaluation, assays and treatment of pkal-mediated disorders
JP7412616B2 (ja) 接触活性化系に関連する疾患のタンパク質バイオマーカー
NZ792391A (en) RNA biomarkers for hereditary angioedema
WO2024003617A2 (en) Protein biomarkers for lanadelumab treatment

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: DYAX CORP., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEXTON, DANIEL J.;VISWANATHAN, MALINI;FAUCETTE, RYAN;AND OTHERS;SIGNING DATES FROM 20200219 TO 20200708;REEL/FRAME:053618/0508

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DYAX CORP.;REEL/FRAME:055772/0327

Effective date: 20210226

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE